Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Latest Information Update: 11 Feb 2022
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms SERAPHIN OL
- Sponsors Actelion Pharmaceuticals
Most Recent Events
- 28 Jan 2021 Status changed from active, no longer recruiting to completed.
- 04 Nov 2020 Planned End Date changed from 30 Sep 2020 to 30 Nov 2020.
- 04 Nov 2020 Planned primary completion date changed from 30 Sep 2020 to 30 Nov 2020.